Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218396

SCHEMBL23218396

SCHEMBL23218396

CCOC(=O)Cc1ccccc1OCc1coc2c(NCC3CCOC3)cc(Cl)cc12

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 1/20 0.34
▸ PTGER1 P34995 3/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ TBXAS1 P24557 1/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ GABRA5 P31644 1/20 0.32
▸ TRPC5 Q9UL62 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.31
▸ PTGDR2 Q9Y5Y4 1/20 0.31
▸ PTGER4 P35408 1/20 0.31
▸ GPBAR1 Q8TDU6 1/20 0.31
▸ BRD4 O60885 1/20 0.31
▸ CFD P00746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852609 1.00 LRRK2 (0.34) LRRK2PTGER1MEN1KMT2AMAPT
SCHEMBL23218917 0.92 PTGER4 (0.38) MEN1KMT2AMAPTTP53THRB
SCHEMBL29852993 0.92 PTGER4 (0.38) MEN1KMT2AMAPTTP53THRB
SCHEMBL29852426 0.91 PTGER4 (0.35) MEN1KMT2AMAPTTP53THRB
SCHEMBL23219001 0.91 PTGER4 (0.35) MEN1KMT2AMAPTTP53THRB
SCHEMBL29591282 0.91 PTGER4 (0.35) MEN1KMT2AMAPTTP53THRB
SCHEMBL23219081 0.86 HPGD (0.42) MEN1KMT2AMAPTNPSR1
SCHEMBL29853156 0.86 HPGD (0.42) MEN1KMT2AMAPTNPSR1
SCHEMBL29852898 0.86 HPGD (0.42) MEN1KMT2AMAPTNPSR1
SCHEMBL23218123 0.85 MAPT (0.38) MEN1KMT2AMAPTTP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 LRRK2 1573/4885PTGER1 602/4885MEN1 757/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB LRRK2 2640/4885PTGER1 1339/4885MEN1 1819/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB LRRK2 3382/4885PTGER1 1089/4885MEN1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.